The stock of Ensysce Biosciences Inc (NASDAQ: ENSC) has decreased by -8.42 when compared to last closing price of 0.30.Despite this, the company has seen a loss of -17.38% in its stock price over the last five trading days. accesswire.com reported 2024-09-24 that ~ New Data on Opioid Use Disorder Program at Society for Neuroscience Meeting ~ ~ Ensysce CEO Invited Expert Speaker at Formulation & Delivery US 2024 Meeting ~ SAN DIEGO, CA / ACCESSWIRE / September 24, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (“Ensysce” or the “Company”), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced its participation in two upcoming meetings in October 2024. October 5, 2024: New data will be presented in a poster session in collaboration with Sygnature Discovery at the Society for Neuroscience meeting in Chicago in the session for Addictive Drugs: Drug Tolerance, Dependence, and Toxicity.The poster entitled “Methadone ameliorates the effects of morphine withdrawal in a modified rat model of physical dependence” is the first study of its kind in a pre-clinical model to evaluate the efficacy of novel agents for treating Opioid Use Disorder (OUD).OUD affects 16 million people worldwide and can be attributed to 500,000 deaths each year.
Is It Worth Investing in Ensysce Biosciences Inc (NASDAQ: ENSC) Right Now?
Company’s 36-month beta value is 0.86.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ENSC is 11.01M, and currently, short sellers hold a 1.85% ratio of that floaft. The average trading volume of ENSC on September 27, 2024 was 1.79M shares.
ENSC’s Market Performance
ENSC stock saw a decrease of -17.38% in the past week, with a monthly decline of -57.65% and a quarterly a decrease of -49.08%. The volatility ratio for the week is 7.37%, and the volatility levels for the last 30 days are 8.85% for Ensysce Biosciences Inc (ENSC). The simple moving average for the past 20 days is -23.79% for ENSC’s stock, with a -62.12% simple moving average for the past 200 days.
ENSC Trading at -31.52% from the 50-Day Moving Average
After a stumble in the market that brought ENSC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.75% of loss for the given period.
Volatility was left at 8.85%, however, over the last 30 days, the volatility rate increased by 7.37%, as shares sank -56.42% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -41.70% lower at present.
During the last 5 trading sessions, ENSC fell by -17.38%, which changed the moving average for the period of 200-days by -74.96% in comparison to the 20-day moving average, which settled at $0.3404. In addition, Ensysce Biosciences Inc saw -74.25% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ENSC
Current profitability levels for the company are sitting at:
- -6.72 for the present operating margin
- -2.72 for the gross margin
The net margin for Ensysce Biosciences Inc stands at -7.84. The total capital return value is set at -6.49. Equity return is now at value -380.55, with -246.41 for asset returns.
Based on Ensysce Biosciences Inc (ENSC), the company’s capital structure generated 0.2 points at debt to capital in total, while cash flow to debt ratio is standing at -21.83. The debt to equity ratio resting at 0.25. The interest coverage ratio of the stock is -5.93.
Currently, EBITDA for the company is -10.72 million with net debt to EBITDA at 0.06. When we switch over and look at the enterprise to sales, we see a ratio of 1.73. The receivables turnover for the company is 6.41for trailing twelve months and the total asset turnover is 0.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.88.
Conclusion
In a nutshell, Ensysce Biosciences Inc (ENSC) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
